Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - bacillus clausii -

Malta - angļu - Medicines Authority

morningside healthcare limited unit c, harcourt way, leicester, le19 1wp, united kingdom - isoniazid - tablet - isoniazid 100 mg - antimycobacterials

Izraēla - angļu - Ministry of Health

remedix care ltd - ascorbic acid; biotin; cocarboxylase tetrahydrate; colecalciferol; cyanocobalamin; dexpanthenol; folic acid; nicotinamide; pyridoxine (vit b6) hydrochloride; retinol palmitate; riboflavine; tocopherol - powder for solution for injection - retinol palmitate 3500 iu/vial; colecalciferol 220 iu/vial; tocopherol 10.2 mg/vial; ascorbic acid 125 mg/vial; riboflavine 5.67 mg/vial; pyridoxine (vit b6) hydrochloride 5.5 mg/vial; cyanocobalamin 0.006 mg/vial; folic acid 0.414 mg/vial; dexpanthenol 16.15 mg/vial; biotin 0.069 mg/vial; nicotinamide 46 mg/vial; cocarboxylase tetrahydrate 5.8 mg/vial - combinations - combinations - vitamin supplementation in patients receiving parenteral nutrition. only for adults and children over 11 years of age.

Īrija - angļu - HPRA (Health Products Regulatory Authority)

medac gesellschaft für klinische spezialpräparate mbh - bacillus calmette guérin (bcg) - powder and solvent for intravesical suspension - unknown - other immunostimulants; bcg vaccine

Īrija - angļu - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - retinol palmitate; colecalciferol; dl-alfa tocoferol; ascorbic acid; pyridoxine hydrochloride; cyanocobalamin; folic acid; dexpanthenol; biotin; nicotinamide; cocarboxylase tetrahydrate; riboflavin sodium phosphate - powder for solution for injection/infusion - n/a - multivitamins, plain

Malta - angļu - Medicines Authority

sanofi malta limited - isoniazid; rifampicin - coated tablet - isoniazid 100 mg; rifampicin 150 mg - antimycobacterials

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 100 mg - ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: - ethambutol plus isoniazid - ethambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilized. ethambutol hydrochloride is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgement determines that it may be used. ethambutol hydrochloride is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sti pharma llc - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with ethambutol hcl have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilized. ethambutol hcl is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. ethambutol hcl is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sti pharma - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hci is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with ethambutol hci have included cycloserine, ethionamide, pyrazinamide, viomycin a

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - isoniazid - solution for injection - 25mg/1ml